The Navifus System has been getting an IDE qualification and a FIH clinical trial for rGBM patients

by NaviFUS
in 2018
on 29/01/2018

The NaviFus Focus Ultrasound System has been getting investigational Device Exemption (IDE) qualification and accepted to execute FIH clinical trial in Q1 for rGBM patients by TFDA Consulting.
It’s a pioneer of brain tumor therapy by using FUS opening BBB temporally in Taiwan’s clinical study. In addition to brain tumors, it is also actively expanding the use of this technology in other central nervous diseases, such as Alzheimer’s disease, epilepsy and so on…